59 related articles for article (PubMed ID: 7773126)
1. Uptake site of lansoprazole, a proton pump inhibitor, in human fundic mucosa: possible relevance with fibroblast and Helicobacter pylori.
Nakamura M; Oda M; Akiba Y; Inoue J; Ito T; Fujiwara T; Tsuchiya M; Ishii H
Cell Mol Biol (Noisy-le-grand); 1995 Feb; 41(1):125-30. PubMed ID: 7773126
[TBL] [Abstract][Full Text] [Related]
2. Autoradiographic demonstration of lansoprazole uptake sites in rat antrum and colon.
Nakamura M; Oda M; Akiba Y; Inoue J; Ito T; Tsuchiya M; Ishii H
J Clin Gastroenterol; 1995; 20 Suppl 2():S8-13. PubMed ID: 7594349
[TBL] [Abstract][Full Text] [Related]
3. Bactericidal activity of lansoprazole and omeprazole against Helicobacter pylori in vitro.
Vogt K; Hahn H
Arzneimittelforschung; 1998 Jun; 48(6):694-7. PubMed ID: 9689430
[TBL] [Abstract][Full Text] [Related]
4. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
Florent C
Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
[TBL] [Abstract][Full Text] [Related]
5. Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori.
Suzuki M; Nakamura M; Mori M; Miura S; Tsuchiya M; Ishii H
J Clin Gastroenterol; 1995; 20 Suppl 2():S93-6. PubMed ID: 7594353
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI.
Ohara T; Morishita T; Suzuki H; Masaoka T; Ishii H
Hepatogastroenterology; 2004; 51(56):338-42. PubMed ID: 15086153
[TBL] [Abstract][Full Text] [Related]
7. Lansoprazole: a comprehensive review.
Zimmermann AE; Katona BG
Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
[TBL] [Abstract][Full Text] [Related]
8. Eradication therapy of Helicobacter pylori directly induces apoptosis in inflammation-related immunocytes in the gastric mucosa--possible mechanism for cure of peptic ulcer disease and MALT lymphoma with a low-grade malignancy.
Ohara T; Kanoh Y; Higuchi K; Arakawa T; Morisita T
Hepatogastroenterology; 2003; 50(51):607-9. PubMed ID: 12828043
[TBL] [Abstract][Full Text] [Related]
9. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
[TBL] [Abstract][Full Text] [Related]
10. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
Güliter S; Keleş H; Ozkurt ZN; Cengiz DU; Kolukisa E
Turk J Gastroenterol; 2005 Mar; 16(1):29-33. PubMed ID: 16252185
[TBL] [Abstract][Full Text] [Related]
11. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
[TBL] [Abstract][Full Text] [Related]
12. Lansoprazole reverses Helicobacter pylori-inhibited gastric epithelial cell growth.
Nakajima N; Kuwayama H; Iwasaki A; Arakawa Y
J Clin Gastroenterol; 1995; 20 Suppl 2():S90-2. PubMed ID: 7594352
[TBL] [Abstract][Full Text] [Related]
13. Lansoprazole and Helicobacter pylori infection.
Pallone F; Luzza F; Delle Fave G; Annibale B; Marcheggiano A; Biancone L; Torsoli A; Capurso L
Clin Ther; 1993; 15 Suppl B():49-57. PubMed ID: 8205595
[TBL] [Abstract][Full Text] [Related]
14. Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH.
Pais SA; Nathwani RA; Dhar V; Nowain A; Laine L
Aliment Pharmacol Ther; 2006 Jun; 23(11):1607-13. PubMed ID: 16696810
[TBL] [Abstract][Full Text] [Related]
15. [Effect of proton pump inhibitors (PPIs) on wound healing of gastric mucosal cell injury].
Masaoka T; Suzuki H; Ishii H
Nihon Rinsho; 2004 Mar; 62(3):556-60. PubMed ID: 15038103
[TBL] [Abstract][Full Text] [Related]
16. [Comparative effect of lansoprazole/amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer].
Kayser S; Flury R; Zbinden R; Fried M; Wirth HP
Schweiz Med Wochenschr; 1997 Apr; 127(17):722-7. PubMed ID: 9221483
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
18. Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer.
Lazzaroni M; Bargiggia S; Bianchi Porro G
Am J Gastroenterol; 1997 Apr; 92(4):649-52. PubMed ID: 9128316
[TBL] [Abstract][Full Text] [Related]
19. Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication.
Kawano S; Murakami M; Saita H; Tsuji S
J Gastroenterol; 1996 Nov; 31 Suppl 9():41-3. PubMed ID: 8959517
[TBL] [Abstract][Full Text] [Related]
20. [Proton pump inhibitor for ulcer therapy. Tolerance profile of lansoprazole].
Müller P; Fuchs W; Peifer-Weiss A; Simon B
Fortschr Med; 1998 Oct; 116(28):31-2. PubMed ID: 9844264
[No Abstract] [Full Text] [Related]
[Next] [New Search]
